Biosimilars Chemotherapy Generic Medicine 
European Pharmaceutical Review
APRIL 30, 2024
If approved, fruquintinib could provide a new oral, chemotherapy-free option as the first and only selective inhibitor of all three vascular endothelial growth factor receptors (VEGFR) receptors approved in the EU for this disease, according to Takeda. This covers paediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.
European Pharmaceutical Review
APRIL 3, 2023
The committee recommended granting a paediatric-use marketing authorisation (PUMA) for Pedmarqsi (sodium thiosulfate) for preventing ototoxicity induced by cisplatin chemotherapy. Ototoxicity is the development of hearing or balance problems due to a medicine. Cisplatin is a chemotherapy used to treat several types of cancer.
Expert insights. Personalized for you.
98 
Let's personalize your content